A 4-amino-acid synthetic peptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, which is produced by the pineal gland. Studied for telomerase activation, telomere elongation, and potential anti-aging effects. Primarily researched in Russia.
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It is based on epithalamin, a peptide extract from the pineal gland first studied by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia.
Epithalon is primarily studied for its reported ability to activate telomerase — the enzyme that lengthens telomeres (the protective caps on chromosome ends). Telomere shortening is one of the hallmarks of aging, and telomerase activation is a major area of anti-aging research. However, the evidence base is primarily from Russian research groups, and independent replication is limited.
Epithalon (also spelled Epitalon) was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Khavinson's research group has published extensively on "bioregulatory peptides" — short peptides (typically 2-4 amino acids) that they propose act as gene regulators, influencing protein expression in specific tissues. Epithalon is the most well-known of these bioregulatory peptides.
The telomerase activation claim is based on in vitro studies showing that Epithalon increases telomerase activity in human somatic cells and in vivo rodent studies showing extended lifespan in treated animals. However, the research has significant limitations: most studies come from a single research group, the mechanisms are not fully elucidated, and no randomized controlled trials in humans have been completed. The relationship between telomerase activation and anti-aging is also complex — while telomere shortening is associated with aging, telomerase activation also occurs in cancer cells, raising theoretical safety concerns.
Epithalon is not approved in any major jurisdiction and remains an investigational compound. It is primarily available through compounding pharmacies and research peptide vendors.
The proposed mechanism is that Epithalon stimulates expression of the hTERT gene, which encodes the reverse transcriptase catalytic subunit of telomerase. In most somatic cells, hTERT is epigenetically silenced after embryonic development, leading to progressive telomere shortening with each cell division. Reactivating hTERT — even partially — could restore telomere maintenance and extend replicative capacity.
| Pathway | Effect | Significance |
|---|---|---|
| Telomerase activation | Increases hTERT expression in somatic cells | Reported to restore telomere length in human fibroblasts |
| Melatonin regulation | Stimulates pineal gland melatonin production | May improve sleep quality and circadian rhythm |
| Antioxidant effects | Increases SOD and other antioxidant enzyme activity | Reduces oxidative stress — a driver of telomere shortening |
| Cell cycle regulation | Normalizes cell cycle in senescent cells | May delay entry into senescence |
| Study | Design | Findings | Level |
|---|---|---|---|
| Telomerase activation | In vitro, human fibroblasts | Epithalon treatment increased telomerase activity and telomere length in cultured human cells (Khavinson lab) | Preclinical |
| Lifespan studies | Animal (mice, rats, Drosophila) | Some studies report increased lifespan (10-15% in mice), improved immune function, and delayed tumor onset | Preclinical |
| Human clinical (Russian) | Clinical study, elderly patients | Reported improvements in immune markers, melatonin levels, and mortality over 6-year follow-up (Khavinson et al.) | Level II-III (limited) |
| Retinal health | Animal studies | Protected retinal cells from degeneration in aging rats | Preclinical |
Limited safety data: No formal Phase I-III safety studies have been conducted for Epithalon. Safety information comes primarily from Russian clinical observations and animal studies published by the Khavinson group. In these studies, no significant adverse effects were reported at standard doses (5-10 mg daily for 10-20 day cycles).
Telomerase and cancer: The theoretical concern with telomerase activation is cancer risk — telomerase is reactivated in approximately 85-90% of human cancers, and it is a mechanism by which cancer cells achieve immortality. Whether exogenous telomerase activation via Epithalon could promote tumorigenesis is unknown. Most clinicians recommend against use in patients with active cancer or a recent cancer history.
Administration: Typically administered as subcutaneous injection at 5-10 mg daily for 10-20 day cycles, repeated every 4-6 months. This cyclic dosing pattern is part of Khavinson's bioregulatory peptide protocol but has not been validated in controlled clinical trials.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved. Not reviewed. |
| Russia | Studied extensively at government research institutes. Not formally approved as a drug. |
| WADA | Not specifically listed |